Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.25 HKD | +3.49% | +13.40% | +8.80% |
Apr. 29 | Wall Street Cues, Property Outlooks Lift Asian Stock Markets | MT |
Apr. 29 | China, Hong Kong stocks rise, led by property shares | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 7.2 and 6.55 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.12 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.80% | 8.59B | C | ||
+21.25% | 72.78B | C+ | ||
-1.78% | 24.24B | C+ | ||
+9.15% | 8.38B | B | ||
-17.39% | 8.09B | B- | ||
+7.33% | 4.81B | B- | ||
+17.69% | 4.32B | B+ | ||
-3.66% | 4.05B | B- | ||
-2.54% | 3.93B | B | ||
+29.14% | 3.79B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1099 Stock
- Ratings Sinopharm Group Co. Ltd.